RGD peptide-conjugated multimodal NaGdF4:Yb3+/Er 3+ nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 96-103

  Lee, Junghan ^a   Lee, Tae Sup ^b   Ryu, Jiyoung ^a   Hong, Sukmin ^a   Kang, Moonsik ^a   Im, Kangbin ^a   Kang, Joo Hyun ^b   Lim, Sang Moo ^b   Park, Sun ^c   Song, Rita ^a  

^a Institute Pasteur Korea   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Ajou University School of Medicine   (South Korea)

Author keywords

Cancer diagnosis; MRI; PET; RGD peptide; Upconversion luminescence; Upconversion nanophosphors

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID CONJUGATED UPCONVERSION NANOPHOSPHOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG COATING; DRUG CONJUGATION; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LUMINESCENCE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; DIMERIZATION; ERBIUM; FEASIBILITY STUDIES; FLUORIDES; GADOLINIUM; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; IODINE RADIOISOTOPES; LUMINESCENT AGENTS; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MICE; MOLECULAR IMAGING; NANOSTRUCTURES; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; YTTERBIUM;

EID: 84872027783     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.108043     Document Type: Article

References (30)

1. Gunasekera UA, Pankhurst QA, Douek M. Imaging applications of nanotechnology in cancer. Target Oncol. 2009;4:169-181.
2. Louie A. Multimodality imaging probes: design and challenges. Chem Rev. 2010;110:3146-3195.
3. Choi JS, Park JC, Nah H, et al. A hybrid nanoparticle probe for dual-modality positron emission tomography and magnetic resonance imaging. Angew Chem Int Ed Engl. 2008;47:6259-6262.
4. Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008;49:1371-1379.
5. Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/ magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med. 2008;38:199-208.
6. Xie H, Wang ZJ, Bao A, Goins B, Phillips WT. In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts. Int J Pharm. 2010;395:324-330.
7. Yi G, Chow G. Synthesis of hexagonal-phase NaYF4:Yb,Er and NaYF4:Yb,Tm nanocrystals with efficient up-conversion fluorescence. Adv Funct Mater. 2006; 16:2324-2329.
8. 4:Yb,Er core and core/shell-structured nanocrystals. J Phys Chem C. 2007;111:13721-13729.
9. Wang F, Liu X. Recent advances in the chemistry of lanthanide-doped upconversion nanocrystals. Chem Soc Rev. 2009;38:976-989.
10. Cheng L, Yang K, Zhang S, Shao M, Lee S, Liu Z. Highly-sensitive multiplexed in vivo imaging using pegylated upconversion nanoparticles. Nano Res. 2010; 3:722-732.
11. Yu XF, Sun Z, Li M, et al. Neurotoxin-conjugated upconversion nanoprobes for direct visualization of tumors under near-infrared irradiation. Biomaterials. 2010;31:8724-8731.
12. Cheng L, Yang K, Shao M, Lee S, Liu Z. Multicolor in vivo imaging of upconversion nanoparticles with emissions tuned by luminescence resonance energy transfer. J Phys Chem C. 2011;115:2686-2692.
13. 3+ monodisperse nanocrystals. Nano Lett. 2007; 7:847-852.
14. 3+ nanoparticles with magnetic and upconversion imaging properties. J Phys Chem C. 2010;114:21077-21082.
15. 3+ co-doped NaYF4 nanophosphors for multimodality PET/MR/UCL imaging. Biomaterials. 2011;32:1148-1156.
16. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 1999;397:534-539.
17. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
18. Cai W, Shin DW, Chen K, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006;6:669-676.
19. Benezra M, Penate-Medina O, Zanzonico PB, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011;121:2768-2780.
20. Kim YH, Jeon J, Hong SH, et al. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small. 2011;7:2052-2060.
21. 3 integrin expression. J Nucl Med. 2007; 48:1162-1171.
22. Im KB, Kang MS, Kim J, et al. Two-photon spectral imaging with high temporal and spectral resolution. Opt Express. 2010;18:26905-26914.
23. 124I using (p,2n) reaction. J Labelled Comp Radiopharm. 2007;50:511-512.
24. 18F-FDG imaging of lung metastasis tumors using small animal PET. Nucl Med Biol. 2008;35: 143-150.
25. 3 expression. Bioconjug Chem. 2011;22:913-922.
26. 4 nanocrystals with improved upconversion fluorescence and MR relaxivity. Nanotechnology. 2010;21:125602-125608.
27. Park YI, Kim JH, Lee KT, et al. Nonblinking and nonbleaching upconverting nanoparticles as an optical imaging nanoprobe and T1 magnetic resonance imaging contrast agent. Adv Funct Mater. 2009;21:4467-4471.
28. Vetrone F, Naccache R, Mahalingam V, Morgan CG, Capobianco JA. The active-core/ active-shell approach: a strategy to enhance the upconversion luminescence in lanthanide-doped nanoparticles. Adv Funct Mater. 2009;19:2924-2929.
29. 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011;32:4151-4160.
30. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003;55:403-419.